Company Overview of Galderma S.A.
Galderma S.A. researches, develops, manufactures, and supplies dermatological products, and aesthetic and corrective medical solutions. It focuses on developing products for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis (fungal nail infections), pigmentary disorders, and skin cancer, as well as medical aesthetic and corrective solutions for skin senescence. The company also provides products for skin structure, dry skin, atopic dermatitis, scalp psoriasis, rosacea, seborrheic dermatitis, and other conditions. It sells products through a network of distributors and representatives worldwide. The company was founded in 1981 and is headquartered in Lausanne, Sw...
Avenue Gratta-Paille 2
World Trade Center
Founded in 1981
Key Executives for Galderma S.A.
Director of Finance, Director of Global Operations and Director of Corporate Services
Senior Director of Organizational Health
Corporate Development Director
General Manager of Spain and Portugal Operations
General Manager of Germany Operations
Compensation as of Fiscal Year 2017.
Galderma S.A. Key Developments
Galderma Presents at Russian Pharmaceutical Forum, May-16-2017
Mar 24 17
Galderma Presents at Russian Pharmaceutical Forum, May-16-2017 . Venue: Corinthia Saint-Petersburg Hotel, 57 Nevskij Prospect, St. Petersburg 191025, Russia.
Bioventus Announces New Agreement with Galderma
Dec 14 16
Bioventus announced it has a new agreement with Galderma for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. Financial terms of the transaction were not disclosed. Bioventus plans to file a premarket approval application with the FDA in early 2017 to bring DUROLANEto the US market in the near future. It owns the international rights to the productand has commercialized it outside of the United States for nearly 15 years. Bioventus currently markets and sells it in more than 25 countries including Canada, Mexico, Australia and much of Europe. Galderma manufactures DUROLANE and other HA products. The addition of DUROLANE tothe US portfolio for Bioventus will complement its newly launched three-injection HA GELSYN-3 and its popular five-injection HA SUPARTZ FX, giving the company an unmatched offering of options for patients, physicians and payers.
Galderma Receives Positive Opinion Through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel (Adapalene / Benzoyl Peroxide) for Acne Patients
Sep 27 16
Galderma announced that it has received a Positive Opinion from 16 concerned European regulatory agencies for the market approval of EPIDUO 0.3% /2.5% gel (adapalene/benzoyl peroxide), for the cutaneous treatment of acne vulgaris, when comedones, numerous papules and pustules are present. With a once-daily application of EPIDUO 0.3% /2.5% gel in the evening to the entire affected areas of the face and the trunk, early signs of clinical improvement usually appear after 1 to 4 weeks of treatment. Galderma expects EPIDUO 0.3% /2.5% gel to be available in pharmacies in Europe as of 2017. EPIDUO 0.3% /2.5% gel contains a fixed-dose combination of Adapalene (3 mg/g) and Benzoyl Peroxide (BPO, 25 mg/g) as EPIDUO 0.1% /2.5% gel, but with a higher concentration of Adapalene, which provided increased clinical benefit in the subjects with numerous papulopustules treated with EPIDUO 0.3% /2.5% gel compared with the lower strength.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|